GPBAR1 and metabolic dysfunction-associated steatotic liver disease: Relevant clinical experiments have demonstrated that FXR and GPBAR1 signalling can improve hepatic bile acids metabolism and lipid homeostasis thereby preventing the development of NAFLD.39